Ani Pharmaceuticals (ANIP) Debt to Equity: 2011-2025
Historic Debt to Equity for Ani Pharmaceuticals (ANIP) over the last 10 years, with Sep 2025 value amounting to $0.62.
- Ani Pharmaceuticals' Debt to Equity fell 1.25% to $0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.62, marking a year-over-year decrease of 1.25%. This contributed to the annual value of $0.79 for FY2024, which is 36.44% up from last year.
- Latest data reveals that Ani Pharmaceuticals reported Debt to Equity of $0.62 as of Q3 2025, which was down 14.14% from $0.72 recorded in Q2 2025.
- In the past 5 years, Ani Pharmaceuticals' Debt to Equity ranged from a high of $1.07 in Q2 2021 and a low of $0.58 during Q4 2023.
- Over the past 3 years, Ani Pharmaceuticals' median Debt to Equity value was $0.72 (recorded in 2023), while the average stood at $0.70.
- As far as peak fluctuations go, Ani Pharmaceuticals' Debt to Equity tumbled by 31.97% in 2022, and later spiked by 36.44% in 2024.
- Quarterly analysis of 5 years shows Ani Pharmaceuticals' Debt to Equity stood at $0.74 in 2021, then fell by 4.26% to $0.71 in 2022, then decreased by 18.54% to $0.58 in 2023, then surged by 36.44% to $0.79 in 2024, then fell by 1.25% to $0.62 in 2025.
- Its last three reported values are $0.62 in Q3 2025, $0.72 for Q2 2025, and $0.76 during Q1 2025.